PMID- 35055355
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220128
IS  - 2075-4426 (Print)
IS  - 2075-4426 (Electronic)
IS  - 2075-4426 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Jan 4
TI  - Unravelling the Proteomics of HLA-B*57:01(+) Antigen Presenting Cells during 
      Abacavir Medication.
LID - 10.3390/jpm12010040 [doi]
LID - 40
AB  - Type B adverse drug reactions (ADRs) are unpredictable based on the drug's 
      pharmacology and represent a key challenge in pharmacovigilance. For human 
      leukocyte antigen (HLA)-mediated type B ADRs, it is assumed that the 
      protein/small-molecule interaction alters the biophysical and mechanistic 
      properties of the antigen presenting cells. Sophisticated methods enabled the 
      molecular appreciation of HLA-mediated ADRs; in several instances, the drug 
      molecule occupies part of the HLA peptide binding groove and modifies the 
      recruited peptide repertoire thereby causing a strong T-cell-mediated immune 
      response that is resolved upon withdrawal of medication. The severe ADR in 
      HLA-B*57:01(+) patients treated with the antiretroviral drug abacavir (ABC) in 
      anti-HIV therapy is an example of HLA-drug-T cell cooperation. However, the 
      long-term damages of the HLA-B*57:01-expressing immune cells following ABC 
      treatment remain unexplained. Utilizing full proteome sequencing following ABC 
      treatment of HLA-B*57:01(+) cells, we demonstrate stringent proteomic alteration 
      of the HLA/drug presenting cells. The proteomic content indisputably reflects the 
      cellular condition; this knowledge directs towards individual pharmacovigilance 
      for the development of personalized and safe medication.
FAU - Haukamp, Funmilola Josephine
AU  - Haukamp FJ
AD  - Institute for Transfusion Medicine and Transplantat Engineering, Hannover Medical 
      School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
FAU - Gall, Eline
AU  - Gall E
AD  - Institute for Transfusion Medicine and Transplantat Engineering, Hannover Medical 
      School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
FAU - Ho, Gia-Gia Toni
AU  - Ho GT
AD  - Institute for Transfusion Medicine and Transplantat Engineering, Hannover Medical 
      School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
FAU - Hiemisch, Wiebke
AU  - Hiemisch W
AD  - Institute for Transfusion Medicine and Transplantat Engineering, Hannover Medical 
      School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
FAU - Stieglitz, Florian
AU  - Stieglitz F
AUID- ORCID: 0000-0001-8799-560X
AD  - Institute of Toxicology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 
      Hannover, Germany.
AD  - Core Facility Proteomics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 
      Hannover, Germany.
FAU - Kuhn, Joachim
AU  - Kuhn J
AD  - Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Center 
      North Rhine-Westphalia, Ruhr University Bochum, Georgstr. 11, 44801 Bochum, 
      Germany.
FAU - Blasczyk, Rainer
AU  - Blasczyk R
AUID- ORCID: 0000-0003-3875-3190
AD  - Institute for Transfusion Medicine and Transplantat Engineering, Hannover Medical 
      School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
FAU - Pich, Andreas
AU  - Pich A
AUID- ORCID: 0000-0001-8444-0940
AD  - Institute of Toxicology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 
      Hannover, Germany.
AD  - Core Facility Proteomics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 
      Hannover, Germany.
FAU - Bade-Doding, Christina
AU  - Bade-Doding C
AUID- ORCID: 0000-0002-5826-1989
AD  - Institute for Transfusion Medicine and Transplantat Engineering, Hannover Medical 
      School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
LA  - eng
GR  - MED1912/Hector-Stiftung/
PT  - Journal Article
DEP - 20220104
PL  - Switzerland
TA  - J Pers Med
JT  - Journal of personalized medicine
JID - 101602269
PMC - PMC8781935
OTO - NOTNLM
OT  - HLA-B*57:01
OT  - abacavir
OT  - adverse drug reaction
OT  - hypersensitivity
OT  - proteome
COIS- The authors declare no conflict of interest.
EDAT- 2022/01/22 06:00
MHDA- 2022/01/22 06:01
PMCR- 2022/01/04
CRDT- 2022/01/21 01:11
PHST- 2021/12/02 00:00 [received]
PHST- 2021/12/21 00:00 [revised]
PHST- 2021/12/30 00:00 [accepted]
PHST- 2022/01/21 01:11 [entrez]
PHST- 2022/01/22 06:00 [pubmed]
PHST- 2022/01/22 06:01 [medline]
PHST- 2022/01/04 00:00 [pmc-release]
AID - jpm12010040 [pii]
AID - jpm-12-00040 [pii]
AID - 10.3390/jpm12010040 [doi]
PST - epublish
SO  - J Pers Med. 2022 Jan 4;12(1):40. doi: 10.3390/jpm12010040.